Andersen-Tawil Syndrome Market Analysis by Disease (Type 1, Type 2), by Drug Class (Carbonic anhydrate Inhibitors, Acetazolamide, Dichlorpenamide, Antiarrhythmic drugs), by Distribution Channel & Region - Global Forecast 2020-2030

Introduction

Andersen-Tawil syndrome is considered a rare form of periodic paralysis and is a type of long QT syndrome. The Andersen- tawil syndrome leads to changes in heart rhythm (arrhythmia). Episodes of muscle weakness and developmental abnormalities is also observed in patients with Andersen-tawil syndrome.

Head, face, and limbs are primarily affected in the physical abnormalities associated with this condition. Andersen-Tawil syndrome is caused by mutations in the KCNJ2 gene in some cases. While in other cases, the associated gene is unknown. The KCNJ2 gene mutation can be inherited in an autosomal dominant manner and occur randomly for unknown reasons (sporadically).

It is estimated that the patients suffering from diseases such as diabetes and cardiovascular diseases are at a higher risk to develop andersen-tawil syndrome. Therefore, the rise in prevalence of these diseases may also lead a rise in the number Andersen-Tawil Syndrome cases.introduction

Andersen-Tawil Syndrome Market: Drivers and Restraints

Increase in the prevalence of Andersen-tawill syndrome is expected to drive the growth of the market. The increasing focus of the government to prioritize drugs for the treatment of rare diseases may also propel the growth of the Andersen-tawil syndrome market during the forecast period. The increasing participation of organizations to support the treatment and to create awareness is also expected to drive the growth of the market. The rising R&D investments by the key players in the Andersen-Tawil Syndrome Market is also expected to boost the growth of the market.

However, the lack of large clinical studies may restrict the growth of the Andersen-tawil syndrome market. The shortage of healthcare expects in Middle East & Africa and Latin America may restrain the growth of the Andersen-Tawil Syndrome market in this region.

Andersen-Tawil Syndrome Market: Overview

Based on disease type, type 1 Anderson-Tawil syndrome is expected to hold a larger share in the Anderson-tawil market. As type 1 is caused by a known KCNJ2 gene mutation making it easier to identify and commence the treatment of the disease.

In the drug class segment, carbonic anhydrate inhibitors and beta blockers are expected to dominate the Anderson-tawil syndrome market during the forecast period.

Andersen-Tawil Syndrome Market: Regional-Wise Outlook

Geographically, the Andersen-Tawil Syndrome Market is segmented into seven regions viz. South Asia, East Asia, Europe, Latin America, North America, Oceania and Middle East and Africa.

North America is expected to dominate the market owing to high healthcare expenditure. The availability of state of the art healthcare facilities in this region is also expected to drive the growth of the Andersen-Tawil Syndrome Market. The availability of funds for research and government support are factor that makes Europe the second largest market for Andersen-Tawil Syndrome.

South Asia is expected to experience fastest growth in the Andersen-Tawil Syndrome market. This is due to improving healthcare infrastructure along with a rise in the no. of cases suffering from the disease. In addition, rising awareness may also help to drive the growth of the Andersen-Tawil Syndrome market at a faster rate in this region. The developing private healthcare in countries like India may also lead to contributing towards the growth of Andersen-Tawil Syndrome market.

However, limited technological advancement, slow economic growth and absence of major players in the Middle East and Africa will lead to limited growth of Andersen-Tawil Syndrome Market in this region.

Andersen-Tawil Syndrome Market: Key players

Some of the players identified in the Andersen-Tawil Syndrome Market include:

• Teva Pharmaceuticals Ltd.
• Zydus Pharmaceuticals, Inc.
• Sun Pharmaceuticals Industries Ltd.
• Advanz Pharmaceticals
• Novartis AG
• Mylan N.V.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology Matrix
• Value Chain

Regional analysis of the Andersen-Tawil Syndrome Market market report includes

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Andersen-Tawil Syndrome Market marketReport Highlights:

• Overview of Global Healthcare Market
• Evolution of the technology
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint.

https://rarediseases.org/rare-diseases/andersen-tawil-syndrome/

Andersen-Tawil Syndrome Market market: segmented

Tentatively, the global Andersen-Tawil Syndrome Market has been segmented on the basis of disease type, drug-class and distribution channel.

Based on disease type, the global Andersen-Tawil Syndrome Market is segmented as:

• Type 1
• Type 2

Based on Drug-class, the global Andersen-Tawil Syndrome Market is segmented as:

• Carbonic anhydrate Inhibitors
• Acetazolamide
• Dichlorpenamide
• Antiarrhythmic drugs
• Amiodarone
• Flecainide
• Beta-Blockers
• Atenolol

Based on distribution channel, the global Andersen-Tawil Syndrome Market is segmented as:

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy